Specialty drugs continue to skyrocket by FDA approvals as well as price. In 2018, high dollar specialty drugs accounted for 44 of the total 59 FDA-approved novel drugs. NPR reported on a recent study which found that specialty drug prices rose 21 percent for oral medications and 13 percent for […]
The Global Use of Medicine in 2019 and Outlook to 2023
The global outlook for medicine use and spending affects the prospects of life sciences companies, insurers and the health of populations around the world. This report includes the latest predictions for the global pharmaceutical market along with geographic, therapy area and channel perspectives. […]
Breaking Through the Hype of Real-World Evidence
Given the increasing availability of real-world health data, the development of credible analyses to help fill the knowledge gap between clinical trials and actual clinical practice is more important than ever. In this white paper, we discuss the expanding use of real-world evidence in healthcare […]
Time to Market: Accelerating Market Access
Getting to market faster clearly has benefits, but there are also potential downsides for drug companies, too. You need to know the options and consider the wider implications. The options for faster market access multiplied in the last three years, with new opportunities available both before and […]
Orphan Drugs in the United States
In the thirty-five years since the passage of the Orphan Drug Act (ODA) in 1983, the structure of development incentives laid out in the legislation has successfully spurred investment and innovation in rare disease therapies. Recent legislative discussion has focused on whether the ODA development […]
Charting Real World Data and Evidence – Activity and Capabilities (2018)
From Patent to Patient: Analyzing Access to Innovative Cancer Drugs
Transitioning Payment Models: Fee-for-Service to Value-Based Care
In a survey of the NEJM Catalyst Insights Council in July 2018, 42% of respondents say they think value-based reimbursement models will be the primary revenue model for U.S. health care. Indeed, this transition is already happening. Respondents report that a quarter of reimbursement at their […]
How Health Plans and Providers Can Collaborate to Improve Care Transitions and Reduce Hospital Readmissions
Download this white paper to learn how sustainable connectivity among physicians, hospitals, caregivers, and patients can help reduce hospital readmissions through the utilization of:Comprehensive data and analytics for patient identification and stratification. Improved care […]
Generating Consensus and Trust for Quality Measurement to Support Value-Based Care
Quality measurement is an integral part of value-based care, yet providers and payers both struggle to define meaningful metrics and leverage quality measurement data to effectively improve care. With more and more revenue shifting into payment models that require all stakeholders to agree on […]
An Evidence-Based Approach to Hiring: Leaders, Physicians, Nurses, and Front Line Staff
The evolution of "evidence-based" medicine changed the healthcare industry. Not that long ago, clinical judgement, anecdotal evidence, and personal experience ruled clinical decision making. Then we discovered that using research to drive decision making, treatment guidelines, and policies vastly […]
Big Data in Pharmaceuticals: Big Opportunities or Big Challenges – or Both?
Every aspect of pharmaceutical research and development involves the generation of huge quantities of data, with the expectation that we can turn this information rapidly into useful knowledge. This can be used to make "data-driven" decisions to better understand and control processes. This derived […]
AHIP Executive Roundtable Discussion Summary
At an event hosted by FierceHealthPayer, sponsored by Medecision, a select group of health insurance executives from across the country gathered in San Diego during the AHIP Institute & Expo to discuss where the healthcare industry is on its journey toward integrating population health models […]
It Takes Two to Tango
Medtech companies are working hard to build better partnerships with IDN customers. However, based on new ZS research, most IDN executives are dissatisfied with the nature of their relationships with medtech suppliers. Medtech leaders apparently recognize the disconnect. In fact, only 25% of the […]
Real World Data Capabilities: Benchmarking Pharma Companies
Defining Real World Data and Real World Evidence Real World Data (RWD) are data used for decision making that are not collected in conventional randomised controlled trials (RCTs). Real World Evidence (RWE) is the evidence generated from RWD. A linked concept is ‘Big Data,’ which is generated from […]
Health Care USA: A Cancer on the American Dream
Via Council for Affordable Health Coverage The widely reported waning of the American Dream has been blamed on a litany of economic and cultural currents, but the cost of the U.S. health care system rarely makes the list. The U.S. spends at least 7 percent more of its GDP on health care than other […]
The Utility of ICER Reports for Private Payer Drug Coverage Decision-Making: Cost-Effectiveness Assessments
U.S. private health care payers, including insurers and self-insured employers, provide health insurance to more than 200 million people. These private payers face relentless medical inflation in an environment where many other business expenses have been constrained. Drug spending has received […]
Advancing Biosimilar Sustainability in Europe
A Holistic Approach to Payment Accuracy Helps Drive Cost Savings
Our end-to-end payment accuracy portfolio leverages proven solutions to help payers address each stage of the payment process more effectively – from pre-submission through post-pay audit and recovery. The cohesive approach helps identify trends that lead to ongoing process improvements, improving […]
Improving Patient Matching with a Simple Plug-In
Accurate patient matching is becoming 10 times more challenging and 10 times more critical. Instantly and dramatically improve your EHR’s or EMPI’s patient matching without disrupting any of its core functionality. By injecting the power of Referential Matching, you will get the full value from […]
Real-World Evidence in the Cloud: How Technology is Revealing the Big Picture in Pharma
The collection and analysis of data generated outside of restricted clinical trials is now critical to pharma companies. Life science companies are responding with Real World Evidence (RWE) programs to capture data from clinical through post-market activities from a variety of sources. The […]
How Payers Can Save an Average of $25,579 Per Patient by Eliminating Unwarranted, Non-Evidence-Based Cancer Treatment
ICER’s Reference Case for Economic Evaluations: Principles and Rationale
To encourage consistency in analytic approaches when modeling, ICER has defined a "reference case" specifying the approach that ICER and its collaborators follow for cost-effectiveness analyses. The reference case is defined by the components, methods, and reporting elements to be used in a […]
